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Abstract
In Hong Kong, universal varicella vaccination started in July 2014. Before this, children could
receive varicella vaccine via the private market. We analysed the epidemiology of varicella and
zoster before universal vaccination. We estimated varicella vaccination coverage through sur-
veys in preschool children. We estimated the burden of varicella and zoster with varicella noti-
fications from 1999/00 to 2013/14, Accident and Emergency Department (A&E) attendance
and inpatient admissions to public hospitals from 2004/05 to 2013/14. We fitted a catalytic
model to serological data on antibodies against varicella-zoster virus to estimate the force
of infection. We found that varicella vaccination coverage gradually increased to about 50%
before programme inception. In children younger than 5 years, the annual rate of varicella
notifications, varicella admission and zoster A&E attendance generally declined. The annual
notification, A&E attendance and hospitalisation rate of varicella and zoster generally
increased for individuals between 10 and 59 years old. Varicella serology indicated an age
shift during the study period towards a higher proportion of infections in slightly older indi-
viduals, but the change was most notable before vaccine licensure. In conclusion, we observed
a shift in the burden of varicella to slightly older age groups with a corresponding increase in
incidence but it cannot necessarily be attributed to private market vaccine coverage alone.
Increasing varicella vaccination uptake in the private market might affect varicella transmis-
sion and epidemiology, but not to the level of interrupting transmission.
Introduction
Varicella is an endemic disease in most parts of the world and it is the most commonly
reported notifiable infectious disease in Hong Kong [1]. Varicella vaccination has been effect-
ive in reducing the disease burden of varicella wherein routine use [2–5]. However, vaccination
at low coverage may not lead to an interruption of transmission, and it may even contribute to
a shift of the varicella burden in unprotected individuals towards older ages who are typically
at higher risk for severe outcomes [6]. Vaccines against varicella and herpes zoster have been
available in Hong Kong through the private market since 1996 and 2006, respectively. Varicella
vaccine was included in the Hong Kong Childhood Immunisation Programme (HKCIP) in
July 2014 for children born on or after 1 January 2013 [7]. Under the HKCIP, eligible children
receive monovalent varicella vaccine (mVV) at 12 months of age and combined MMRV (mea-
sles, mumps, rubella and varicella vaccine) during their first year at primary school (about 6
years of age) as a second dose.
We document the varicella vaccination uptake before universal childhood vaccination
alongside serological population profiles and the disease burden of varicella and zoster. We
describe the burden of varicella and zoster in Hong Kong in the pre-universal varicella vaccin-
ation era and its changing epidemiology as a result of varicella vaccination through the private
market.
Methods
Varicella vaccination coverage in pre-school children
The Department of Health (DH) conducted six rounds of territory-wide immunisation surveys
to assess the uptake of different vaccines in preschool children in 2001 [8], 2003 [9], 2006 [10],
2009 [11], 2012 [12] and 2015 [13]. In summary, pre-schools in Hong Kong were selected
using stratified cluster sampling. About 5% of preschools were selected in each survey
(range: 24–71). All parents of the selected preschools were invited to join the survey.
Consented parents completed a self-administered questionnaire to collect demographic
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information on children (including place of birth and residence)
and provide all relevant immunisation records to us through the
pre-primary institutions. During field visits, trained field workers
collected the questionnaires and extracted information from the
immunisation records to a standardised data-recording form.
When the immunisation record was incomplete, parents were
asked to provide other immunisation documents, if any. The
response rate of these six surveys was at least 73% [8–13].
There is a high rate of pre-school attendance amongst children
aged 3–5 years in Hong Kong [14]. Thus, we included children
aged 3–5 years in each survey for analysis and excluded younger
children. Before 2015 only information for the first dose was
recorded for vaccines not included in the routine immunisation
schedule, including varicella vaccines. Date of vaccination was
only collected in the 2015 survey. We defined varicella vaccination
uptake as the proportion of respondents who received at least one
dose of varicella vaccine.
Disease burden of varicella and zoster
We used data of varicella notifications to the DH from 1999 until
2014 which included reports from public and private health sector
physicians and schools. The clinical case definition for such noti-
fications is the acute onset of diffuse (generalised) papulovesicular
rash without other apparent cause or alternatively atypical
(milder) clinical presentation with previous varicella vaccination.
We defined probable cases as those fulfilling the clinical case def-
inition and confirmed cases as probable cases with either labora-
tory confirmation or with known epidemiological links to a
confirmed case [15]. We included all confirmed and probable
cases in our analyses.
Furthermore, we used data on Accident and Emergency
Department (A&E) attendance and inpatient admissions to public
hospitals routinely collected via the Communicable Disease
Information System (CDIS) of the DH. In Hong Kong, public
hospitals account for around 80% of all hospitalisations [16].
Doctors assign ICD-9-CM diagnosis codes for A&E attendance
and inpatient admissions as part of the clinical record. The
main condition contributing to the disease episode is assigned
as the primary (principal) diagnosis code, whereas other contrib-
uting condition(s) are assigned as secondary diagnosis codes. We
included all A&E and inpatient admission records with an
ICD-9-CM code of varicella (052) and/ or zoster (053) in the pri-
mary or secondary diagnosis code. Data from 2004 to 2015 were
available for analyses. In addition, we analysed principal and sec-
ondary diagnosis codes to record the frequency of other common
complications related to varicella and zoster, presence of immune-
compromising conditions and pregnancy, according to a pre-
defined list of ICD-9-CM codes (Table S1). All varicella and
zoster attendance and admissions after the initial diagnosis were
assumed to be part of the same illness episode. We defined the
length of stay for inpatients with multiple varicella or zoster
admissions during one illness episode as the cumulative number
of days in the hospital. Fatal cases were defined based on dis-
charge information in the last admission episodes.
In the fiscal year of 2009/10, the Hospital Authority (HA)
introduced a pay-for-performance funding model to tie
budget allocations with services provided by different hospitals
[17]. In this system, the diagnoses codes are used to measure
workloads [17]. We observed changes in coding practice during
our study period as coding was more complete after 2009/10
(Fig. S1). Therefore, changes in the rate of varicella and zoster
A&E attendance and admission might be affected by the improve-
ment in coding completeness. To account for this change, we
adjusted the annual number of A&E attendances (hospital admis-
sions) that were coded as varicella according to the principal diag-
nosis by the proportion of attendances (admissions) not coded in
the corresponding year and age group relative to the last study
year (2013/14) (Fig. S1). Similarly, we adjusted the annual num-
ber of attendances (admissions) that were coded as varicella
according to the secondary diagnoses by the average number of
codes assigned per attendance (admission) in the corresponding
year and age group relative to the last study year. We similarly
adjusted for a change in coding for zoster.
We defined an epidemiological year as the 12 months from
September to August to account for the seasonality of varicella
disease burden in Hong Kong. We obtained annual age-stratified
population estimates from the Census and Statistics Department
[18] to compute the annual rate of varicella notification, A&E
attendance and hospitalisation. We conducted Poisson (log-
linear) regression to evaluate trends in age-specific annual inci-
dence rates for different surveillance data:
Log(cases)/Log(population)= incidence + trend × year + error,
where the population was included as an offset, year indicated the
number of years before 2013/14 and coefficient (trend) indicated
the annual change in rate with a value of 1 equivalent to no trend.
Varicella serology and force of infection
The Public Health Laboratory Services Branch (PHLSB) of the
DH conducted serological surveillance on antibodies against
varicella-zoster virus (VZV) in 1995, 2000, 2005 and 2010 [19].
Convenience samples were selected from sera submitted for
laboratory tests other than virology. These residual sera were col-
lected until a predefined number was attained for different age
groups. To assess whether increasing vaccine uptake in the private
market had impacted varicella transmission over the study period,
we fitted a single catalytic model [20] to the seroprevalence data
of all 4 years in order to estimate potential changes in the force
of infection (FOI – the annual rate at which susceptible indivi-
duals become infected). We assumed that infants younger than
six months are protected by maternal antibodies. We found that
similar to other studies, more than 90% of adults in our study
had seroconverted at the time of testing [21]. Hence, we assumed
individuals aged 20 years or older contribute little to transmission
and restricted the fitting of our model to data from children. Since
only data for four broad age strata were available for individuals
under 20 years old [19], we estimated and compared the overall
FOI for these individuals in different periods. We further assumed
that the FOI was constant before 1995, and we estimated potential
changes in the force of infection between later surveys. We jointly
estimated those FOIs using a Metropolis–Hastings Markov Chain
Monte Carlo algorithm with a binomial likelihood. The model
equation reads:
z1995(a) = 1− e−lpre·am ,
z2000(a) = 1− e
−l1995·am , a ≤ 5
1− e−l pre·(am−5) · e−l1995·5 , a . 5,
{
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z2005(a) =
1− e−l2000·am , a ≤ 5
1− e−l1995· am−5( ) · e−l2000·5 , 5 , a ≤ 10
1− e−lpre· am−10( ) · e−l1995·5 · e−l2000·5 , a . 10,
⎧⎨
⎩
z2010(a) =
1− e−l2005·am , a ≤ 5
1− e−l2000· am−5( ) · e−l2005·5 , 5 , a ≤ 10
1− e−l1995· am−10( ) · e−l2000·5 · e−l2005·5 , 10 , a ≤ 15
1− e−lpre· am−15( ) · e−l1995·5 · e−l2000·5 · e−l2005·5 , a . 15,
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
where zY(a) is the proportion of seropositive individuals in year Y
and at age a and am = a − 0.5. Further, λpre, λ1995, λ2000, λ2005 are
the FOI before 1995, from 1995 to 1999, from 2000 to 2004 and
from 2005 onwards, respectively.
As varicella vaccine was available in the private market since
1996 and the vaccine uptake increased over the years, some indi-
viduals tested seropositive might have seroconverted through vac-
cination irrespective of natural infection. To adjust for that we
calculated the age-specific proportion of vaccinees in respective
survey years by interpolating results from the coverage surveys,
assuming 65% of them seroconverted [22] (Table S2) and the
remaining proportion of the population could seroconvert due
to natural infection:
z^Y (a) = zY (a) · 1− vY (a)( ) + vY (a),
where z^Y(a)is the adjusted proportion of seropositive individuals
in year Y and at age a, after taking into account the proportion of
seroconversion arising from vaccination (vY(a)) and zY(a) as
defined above.
We conducted a sensitivity analysis on the model fitting by
using data estimated from the 95% confidence bounds of the pro-
portion of vaccinees seroconverted (Fig. S3). Based on the FOI
estimated, we computed the reproduction number corresponding
to each estimated FOI by assuming random mixing and a rect-
angular age distribution as R0 = L · λ [23], where L is the average
life-expectancy in Hong Kong in 1995 [24].
We further estimated the number of new infections IY(a) as the
product of the proportion of seronegative (and hence susceptible),
the annual FOI and the respective population size (PY(a)):
IY (a) = (1− zY (a)) · lY · PY (a).
To assess underreporting of varicella notification, we com-
puted the ratio between the number of notifications and the esti-
mated number of new infections. As age-specific notification data
are not available for 1995, this analysis was limited to 2000, 2005
and 2010 only.
All statistical tests and the catalytic model were programmed
in R [25].
Results
Varicella vaccination uptake in preschool children
Uptake of at least one dose of varicella vaccine among preschool
children gradually increased to about 50% during the decade
before the introduction of the universal varicella vaccination pro-
gramme in Hong Kong (Fig. 1a). For children born in 2009, 2010
and 2011, <10% had received a second dose of varicella vaccine
before the age of 6, 5 and 4 years, respectively. Most children in
these cohorts received the first dose of varicella vaccine before
20 months of age (Fig. 1b).
Disease burden, temporal trends and seasonality of varicella
and zoster
From September 1999 to August 2014, over 173 000 varicella
cases were reported to the DH, corresponding to an average
annual incidence of 156 per 100 000 population. There were
14 144 varicella episodes recorded under A&E attendance and
2860 under inpatient admissions during the same period
(Table 1). Varicella primarily affected young children aged
Fig. 1. Varicella vaccination in preschool children in Hong Kong. (a) Proportion of pre-
school children in Hong Kong receiving varicella vaccine by birth cohort, 1995–2011
and (b) Interquartile range of age at receipt of varicella vaccination (months) for pre-
school children born from 2009 to 2011 by birth cohort and a dose of vaccine calcu-
lated from the survey in 2015. Note: Uptake on the second dose of vaccine was only
recorded for children born in 2009–2011.
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under 10 years. The average annual notification, A&E attendance
and inpatient admission rate decreased with age (Fig. 2a). The
average annual notification rate per 100 000 for those aged 5–9
years and those aged under 5 years were similar (1620 and
1555, respectively). On the other hand, the A&E attendance and
inpatient admission were highest for those aged under 5 years
(202 and 51 per 100 000, respectively).
Four per cent of cases admitted due to varicella were immuno-
deficient (Table 2). Nineteen per cent of female admissions aged
20 years or above were pregnant. Less than 1% of varicella A&E
attendance was associated with complications, compared with
20% in varicella admission (Tables 2).
The number of zoster A&E attendance and inpatient admissions
was higher than that for varicella. Nineteen per cent had multiple
A&E attendance or admissions (Table 1). The median age of zoster
A&E attendance and admissions were 59 and 73 years, respectively.
In contrast to varicella, the average annual A&E attendance and
inpatient admission rate for zoster increased with age (Fig. 2a)
and was highest for those aged 60 years and above (both 117 per
100 000). The rate of zoster admission for those aged 80 years and
above was nearly four times higher than that for those aged 60–79
(Fig. 2a). Complications occurred in 23% of zoster admissions, with
post-herpetic neuralgia (PHN) (13%) and ophthalmic complications
(5%) being the most common (Table 3).
There were no deaths recorded for varicella and zoster A&E
attendance. The crude case-fatality rate of varicella notification,
varicella and zoster admissions were 0.005, 3.1 and 37.6 deaths
per 1000 cases, respectively.
Varicella notifications, A&E attendance and hospitalisations
exhibited strong seasonal patterns with additional inter-season
variation (Figs 2b & c). In contrast, zoster-related A&E attendance
and admission did not show much intra- or inter-season variance
(Figs 2b & c). Both the rate of zoster A&E attendance and
admission increased with age.
Changing epidemiology over time
The estimated coefficients for time trend in the annual rate of
varicella notification, varicella and zoster A&E attendance and
hospitalisations in Hong Kong is presented in Figure 3. In chil-
dren younger than 5 years, the annual rate of varicella notification
(−2.5% (95% CI −2.4 to −2.7%)), varicella admissions (−5.6%
(95% CI −3.7 to −7.5%)) and zoster A&E attendance (−13.3%
(95% CI −5.3 to −21.3%)) generally decreased during the study
period (Fig. 3). The annual notification, A&E attendance and hos-
pitalisation rate of varicella and zoster generally increased for
individuals between 10 and 59 years old, although no significant
changes were observed for some age groups (those aged 10–14
years in zoster A&E attendance, those aged 40–59 years in vari-
cella admission and those aged 10–19 years in zoster admission).
The annual rate of increase was 3.0% (95% CI 1.1–5.0%) to 11.2%
(95% CI 9.5–12.9%) for varicella and 0.2% (95% CI −5.7 to 6.3%)
to 6.8% (95% CI 5.3–8.3%) for zoster. For children aged 5–9 years
and adults of at least 60 years, we found no consistent trend in
either direction.
In addition to varicella notification, varicella serology also
indicated an age shift towards a higher proportion of infections
in slightly older individuals. These changes were most notable
from the period before vaccine licensure to vaccine introduction
in the private market and when the vaccine uptake further
increased in the private market from 2005 onwards (Fig. 4a & b).
The annual FOI before vaccine introduction in the private market
was estimated to be 0.22 (95% CI 0.19–0.25) and it decreased to
0.13 (95% CI 0.10–0.17) from 1995 to 1999. After vaccine
licensure, the FOI from 2000 to 2004 was stable at 0.12
(95% CI 0.10–0.15), but it further reduced to 0.08 (95% CI
0.06–0.11) from 2005 onwards (Fig. 4b). This corresponds to a
reduction in reproduction number from 17.2 (95% CI 15.2–
19.4) to 10.4 (95% CI 7.8–13.5), 9.8 (95% CI 7.8–12.1) and 6.6
(95% CI 4.7–8.7) (Fig. 4b). The estimated average age of infection
increased from 4.6 (95% CI 4.1–5.2) in 1995 to 7.7 (95% CI 5.9–
10.2) in 2000, and 8.3 (95% CI 6.7–10.4) in 2005 and 12.4 (95%
CI 9.4–17.6) in 2010.
Underreporting of varicella notification
When compared with the number of varicella notifications, 13%,
22% and 29% of the estimated varicella infections in 2000, 2005
Table 1. Baseline characteristics of varicella and zoster cases in Hong Kong
Varicella Zoster
Statutory notification
A&E
attendance
Inpatient
admission
A&E
attendance
Inpatient
admission
Study period September 1999–
August 2014
September 2004–August 2014
No. of cases 173 748 14 144 2860 23 456 12 885
No. of cases with multiple attendance/
admission (%)
NA 1470 (10) 164 (6) 4423 (19) 2600 (20)
No. of attendance/
admission
Median
(range)
NA 1 (1–6) 1 (1–11) 1 (1–48) 1 (1–37)
Gender (%) Male 90 355 (52) 7626 (54) 1546 (54) 11 721 (50) 6066 (47)
Female 80 391 (47) 6518 (46) 1314 (46) 11 735 (50) 6819 (53)
Unknown 2002 (1) 0 (0) 0 (0) 0 (0) 0 (0)
Age in years Median
(range)
6 (0–99) 7 (0–92) 6 (0–98) 59 (0–104) 73 (0–110)
CFR (per 1000 cases) 0 0 3 0 38
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and 2010 were reported. The reporting ratio differed by age and
year (Fig. 4c). Reporting was most complete for those aged 3–
10 years.
Discussion
Before the introduction of universal varicella vaccination in Hong
Kong, vaccine uptake through the private market increased
gradually to about 50%. We showed that varicella and zoster are
common diseases in Hong Kong. We observed a shift in the
burden of varicella to slightly older age groups with a correspond-
ing increase in A&E attendance and hospitalisations in these
age groups. We also showed from cross-sectional serological
surveys that the transmission intensity of varicella decreased
while the average age of varicella infection increased shortly
after vaccine licensure. Therefore, the shift in disease burden
Fig. 2. Varicella notification, varicella and zoster A&E attendance and hospitalisation in Hong Kong. (a) The average annual rate of varicella and zoster in Hong
Kong during the study period, (b) relative frequency distribution for cases of all ages by month throughout the study period and (c) rate of varicella and zoster by
epidemiological year. Notification is available only for varicella. Epidemiological year was defined as 12 months from September to August.
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may not be solely associated with the increasing vaccine uptake in
the community.
The annual FOI before vaccine use in the private sector was
estimated to be 0.22 (95% CI 0.19–0.25), which is high compared
with the FOI in Australia before use of varicella vaccine [26] and
comparable with some of the estimates from 11 countries in
Europe [21]. The difference in the intensity and pattern of popu-
lation mixing may contribute to the variations in varicella trans-
mission estimates. It should be noted that varicella transmission
may be facilitated in a densely populated area. The population
density (per square kilometre) in Hong Kong (5758) was much
higher than those in Australia (2) and the 11 countries included
in the European study (15–378), according to estimates of
United Nations in 1995 [27].
The decrease in transmission intensity of varicella was most
prominent from 1995 to 1999, but the initial vaccine uptake dur-
ing this period was low. While the low vaccination uptake might
have had some effect on varicella transmission, other factors such
as temporal changes in contact mixing could have played an add-
itional role. However, the first published social contact data in
Hong Kong were collected in 2009 and 2010 [28] and earlier
data are not available for comparison. Nevertheless, we did
observe some reduction in the overall number of students and
class size in a comparable period from data from the Education
Bureau [29] and Social Welfare Department [30] (Fig. S2).
The age shift in varicella infection leaves unvaccinated indivi-
duals at increased risk of complications that accompany infection
[31]. This includes varicella infection during pregnancy which
can result in transplacental transmission of VZV to the foetus
and lead to stillbirths or permanent congenital defects [32]. Our
analysis of public hospital admissions showed that 19% of
women aged 20 years or older with varicella-related admissions
were pregnant. This overrepresentation of pregnant women
further highlights the need for increased awareness among health-
care workers of the risk of varicella during pregnancy.
Albeit inconclusive from this analysis, if indeed the increased
vaccine uptake in the private sector contributed to the age shift
in varicella burden, it creates an issue of equity as those older
non-immune children not eligible for universal vaccination
would be less likely to acquire natural immunity at a young age.
With the inclusion of varicella vaccine in the Childhood
Immunisation Programme, vaccination uptake should soon
exceed 90% and, in the mid-term, likely prevents the majority
of varicella illnesses during childhood. However, in the short-term
the additional reduction in transmission leaves those cohorts of
children who are too old to be eligible for vaccination and who
have not been vaccinated through the private market at an even
higher risk. We have established a baseline rate which will allow
monitoring to identify trends in varicella complications and act
on them swiftly.
Furthermore, we found that the burden of zoster A&E attend-
ance and hospitalisations in adults has been on the rise in the pre-
universal varicella vaccination era. Circulation of VZV in the
community is believed to boost immunity against zoster for indi-
viduals previously infected with varicella. It is possible that the
gradual increase in varicella vaccination uptake reduced transmis-
sion and hence boosting, leading to the observed increase in zos-
ter A&E attendance and hospitalisations among adults. However,
the estimated annual decrease in varicella notification and admis-
sion for children was 2.5% and 5.6%, and hence effects on trans-
mission may be relatively small. The relationship of childhood
varicella vaccination and adult zoster burden continues to be a
point for discussion [33]. In addition, other temporal changes
might have also contributed to this increase in burden (Fig. S2).
In particular, the change in the incentive to code A&E attendance
and hospital admissions has made such interpretation difficult.
Fig. 2. Continued.
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Table 2. Underlying medical conditions, complications and outcomes of varicella-related A&E attendance and inpatient admissions
A&E attendance in
public hospitals
Inpatient admission
in public hospitals
N % N %
No. of cases 14 144 – 2860 –
Underlying medical conditions
Pregnancya 15 1.2 87 19.0
Immunodeficiency (any)b 0 – 110 3.8
Lymphoproliferative malignancy 0 – 50 1.7
Malignancy of solid organ/tissue 0 – 21 0.7
Transplant 0 – 22 0.8
HIV 0 – 5 0.2
Other immunodeficiency conditionc 0 – 25 0.9
Complicationb 97 0.7 575 20.1
Pneumonia 12 0.1 92 3.2
Varicella pneumonitis 4 0.0 10 0.3
Other pneumonia 8 0.1 82 2.9
Neurological disorder 6 0.0 35 1.2
Encephalitis 0 – 12 0.4
Ataxia 0 – 10 0.3
Meningitis 6 0.0 13 0.5
Myelitis 0 – 2 0.1
Other unspecified viral infection of the central nervous system 0 – 0 –
Septicaemia/sepsis 0 – 21 0.7
Bacterial infections (including scarlet fever and bacterial infection caused by
Streptococcal and Staphylococcal species)
0 – 238 8.3
Bacterial superinfection of skin and/or soft tissue 14 0.1 101 3.5
Cellulitis, abscess and erysipelas 13 0.1 83 2.9
Impetigo 1 0.0 17 0.6
Fasciitis 0 – 3 0.1
Ophthalmic disorders (including conjunctivitis and keratoconjunctivitis) 11 0.1 14 0.5
Congenital varicella infection 0 – 0 –
Outcome
Hospitalisation 563 4.0 NA NA
Median length of stay (days) NA NA 4
Among cases with complications NA NA 5
Among cases without complications NA NA 4
ICU admission NA NA 19 0.7
Among cases with complications NA NA 6 1.0
Among cases without complications NA NA 13 0.6
Death 0 0.0 9 0.3
Among cases with complications – – 6 1.0
Among cases without complications – – 3 0.1
aPregnancy among females aged 20 years or above.
bMore than one type of immunodeficiency/complications were coded in some episode of A&E attendance and admission.
cThese include conditions such as white blood cell diseases, Thalassaemia major, aplastic anaemia, asplenia or other splenic diseases, other specified diseases with the participation of
lymphoreticular and reticulohistiocytic tissue, patients undergoing chemotherapy or radiotherapy and other conditions affecting the immune system.
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While we accounted for such changes in coding for both primary
and secondary diagnoses when estimating the burden of A&E
attendance and hospitalisations, we cannot rule out that such
changes have contributed to our findings of increasing rate of zos-
ter A&E attendance and hospitalisations among adults.
Based on the existing data, we found no evidence of an
increase in zoster A&E attendance and hospitalisation rate
among the two oldest age groups, for which the burden of zoster
disease is highest. However, this observation may have been
affected by a change in healthcare-seeking behaviour instead of
zoster vaccination, for which <10% of those aged 60 years or
above should have received zoster vaccination (personal commu-
nication with Drug Office of the Department of Health).
Specifically, since 2009 the Government introduced Health Care
Vouchers (HCV) for elders aged 70 years or above to subsidise
healthcare costs in the private medical sector (which is not cov-
ered by our zoster data) [34]. The amount of annual subsidy
has increased from $250 in 2009 to $2000 in 2015.
Table 3. Underlying medical conditions, complications and outcomes of zoster-related A&E attendance and inpatient admissions
A&E attendance in public
hospitals
Inpatient admission in public
hospitals
N % N %
No. of cases 23 456 – 12 885 –
Underlying medical conditions
Pregnancya 3 0.0 38 0.6
Immunodeficiency (any) 11 0.0 1952 15.1
Lymphoproliferative malignancy 2 0.0 691 5.4
Malignancy of solid organ/tissue 5 0.0 855 6.6
Transplant 0 0.0 259 2.0
HIV 3 0.0 68 0.5
Other immunodeficiency conditionb 1 0.0 303 2.4
Complication 426 1.8 2989 23.2
Neurological disorders 1920 8.2 2047 15.9
Encephalitis 2 0.0 28 0.2
Meningitis 14 0.1 61 0.5
Post herpetic neuralgia 1848 7.9 1646 12.8
Post herpetic trigeminal neuralgia 35 0.2 65 0.5
Post herpetic polyneuropathy 8 0.0 8 0.1
Viral infection of the nervous system 22 0.1 72 0.6
Ophthalmic complications 699 2.9 627 4.9
Geniculate zoster/Ramsay-hunt syndrome 318 1.4 400 3.1
Auricular involvement 31 0.1 37 0.3
Disseminated zoster 13 0.1 77 0.6
Outcome
Hospitalisation 1485 6.3 NA NA
Median length of stay (days) NA NA 7
Among cases with complications NA NA 8
Among cases without complications NA NA 6
ICU admission NA NA 24 0.2
Among cases with complications NA NA 7 0.2
Among cases without complications NA NA 17 0.2
Death 0 0.0 484 3.8
Among cases with complications – – 117 3.9
Among cases without complications – – 367 3.7
aPregnancy among females aged 20 years or above.
bThese include conditions such as white blood cell diseases, Thalassaemia major, aplastic anaemia, asplenia or other splenic diseases, other specified diseases with the participation of
lymphoreticular and reticulohistiocytic tissue, patients undergoing chemotherapy or radiotherapy and other conditions affecting the immune system.
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Cross-sectional surveys showed that the proportion of the elderly
having ever used HCV increased from 35% in 2010 [35] to 80% in
2015 [36]. Thematic Household Surveys [16] conducted by the
Census & Statistics Department indicated that individuals aged
65 years or above attended more private practitioners but less
A&E doctors in recent years (personal communication with
Census & Statistics Department). The proportion of inpatient
admission at private hospitals increased from 4% in 1999 to
10% in 2014.
Based on the number of varicella infections estimated by fit-
ting the serological data to the catalytic model, only 13–29% of
infections were notified. This is comparable with studies in Italy
[37] and the USA [38], which similarly found that notification
was most complete in children 5–9 years old and that less than
half of varicella cases are notified, albeit using different method-
ologies to estimate underreporting. Varicella is a generally mild
disease and hence parents may be reluctant to seek medical con-
sultation. In particular, Hong Kong parents do not need medical
confirmation if their child is absent from (pre-) school.
Furthermore, doctors may mis-classify particularly mild symp-
toms of varicella. Reporting was most complete in children 3–6
years old in our study. Under the current reporting system,
(pre-) schools are required to report varicella outbreaks and
hence cases that are not usually seen by a doctor could be identi-
fied this way. We also found that reporting was more complete in
later years, potentially related to increased awareness of varicella
after the vaccine was more widely available in the community.
There are several limitations of this study. First, A&E attend-
ance and admission with diagnosis codes for VZV in preg-
nancy/postpartum were not available and this may lead to slight
underestimation of the disease burden. Second, clinical notes
were not available to ascertain the specificity and accuracy of
the ICD codings. For instance, there were one and 21 A&E attend-
ance and hospitalisations coded with both varicella and zoster,
respectively. Likewise, fatal outcomes following varicella and zos-
ter A&E attendance and hospitalisations might be attributed to
other concurrent diseases, which resulted in an apparently high
case-fatality rate of zoster. On the other hand, only 4% and
17% of the hospitalised varicella and zoster cases had codes
related to immune-deficient conditions (Table S1), which were
lower than one US study using similar methodology [39]. This
could be due to the difference in coding practice or criteria in
admitting cases, but it is difficult to ascertain without review of
clinical records. Third, although we adjusted the estimates of vari-
cella and zoster A&E attendance and admissions rate with the
coding rate in respective years, changes in healthcare-seeking
behaviour might vary during the study period. Fourth, residual
sera for the seroprevalence surveys were sampled conveniently
and they might differ from the general population, although a
study in Australia [40] showed that sero-immunity against most
vaccine-preventable diseases estimated from samples collected
through convenient and random sampling were largely compar-
able. Fifth, while commercially available VZV whole-cell (wc)
enzyme-linked immunosorbent assay (ELISA) kits are regarded
as sufficient in detecting seroconversion arising from natural
infection, its reliability in assessing seroconversion from vaccin-
ation is not well documented [41]. In our model, we rely on an
estimate from Sauerbrei et al. [22] for which 37 of 57 (65%
[95% CI 51–77%]) of individuals aged 2–35 years were tested
positive by a commercially available wc ELISA kit 4–6 weeks
after receiving one or two doses of mVV. We conducted sensitiv-
ity analysis on model fitting based on data estimated from the
confidence bounds of Sauerbrei et al.’s work. This showed that
the modelled proportion seropositive was largely comparable
even after taking into account variations in the seroconversion
among vaccinees (Fig. S3). In addition, circulation of wild-type
VZV is believed to boost immunity of previously infected indivi-
duals [42]. There is also evidence of such boosting in the
Fig. 3. Coefficients (trends) of the Poisson regression on the annual rate of varicella notification, varicella and zoster A&E attendance and hospitalsations in Hong
Kong. Notification is available only for varicella. A coefficient of zero indicates no change.
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Fig. 4. Varicella serology and estimated transmission para-
meters in Hong Kong in 1995, 2000, 2005 and 2010.
(a) Proportion seropositive against varicella antibody by ELISA
test (points with error bars representing 95% CI) and model
fitting (line charts with shaded errors bands representing 95%
CI), (b) average age of infection [AvAge], annual average force
of infection [FOI] and basic reproduction number [R] and
(c) reporting ratio between varicella notification and number
of infections estimated. Age-specific data on varicella notifica-
tion are only available for analysis for the year 1999 and
onwards.
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persistence of immunity in vaccinees [43]. Therefore, natural
infection (as indicated by the FOI) might not only contribute to
the seroconversion in those naturally infected but also the vacci-
nees, especially a few years after vaccination. This is particularly
relevant to our study in Hong Kong, as the circulation of VZV
continues among those unvaccinated in the absence of universal
vaccination. The magnitude of such boosting in vaccinees is not
well understood. Sixth, consultations in public and private out-
patient settings account for nearly 80% of all consultations [16],
but zoster data in these settings were not available for a more
comprehensive assessment of the disease burden. Furthermore,
non-residents who sought medical care in Hong Kong may con-
tribute to the burden of varicella and zoster as well as varicella
serology. Importation status was only available for varicella noti-
fications from 1999 to 2003, but imported cases contributed to
only 0.2% of all notifications in this period. This proportion
might have increased in recent years as the number of babies
born in Hong Kong to mainland women was on the rise until
2013 [44]. Although some of these babies are raised in mainland
China, they may later move to Hong Kong for education or
continue to reside in mainland China but travel to Hong Kong
regularly as cross-border students [45]. The impact of these
demographic changes to our observations is unclear as details
are not available.
In conclusion, we establish an estimate of the burden of varicella
and zoster in Hong Kong in the era before universal childhood vac-
cination against varicella. We show that vaccination uptake
increased substantially through private sector access before univer-
sal vaccination; although not to levels that likely interrupt transmis-
sion. We present evidence that during the same time period, the
disease burden of varicella has shifted towards older children
which sees unvaccinated individuals at increased risk of disease
complications. Concurrently we observed an increase in zoster
A&E attendance and hospitalisation rate among young and
middle-aged adults. Serological data extending back to 1995 suggest
that age shifts in varicella infections started before licensure of vari-
cella vaccine and hence cannot necessarily be attributed to private
market vaccine coverage alone. With the decision taken in 2013
to offer universal varicella vaccination in Hong Kong, we expect
the burden of varicella in young children to decline in subsequent
years. However, further research is needed to appraise the necessity
of a catch-up campaign to protect children not currently eligible for
vaccination, the likely impact of different vaccination schedules,
and the cost-effectiveness of the programme.
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